埃索美拉唑联合丽珠维三联根除幽门螺杆菌感染疗效观察

目的研究埃索关拉唑、丽殊维三联根除幽门螺杆菌（Hp）感染的疗效及安全性．方法胃镜提示慢性胃炎、C14呼气试验阳性的122例患者，随机分为治疗组60例，予埃索美拉唑、丽珠维三联治疗；对照组62例，予埃索美拉唑、阿莫西林、甲硝唑治疗，疗程1周。停药后4周复查胃镜及14C尿素呼吸试验。结果治疗组和对照组HP根除率有显著性差异（P〈0．05），症状缓解率、不良反应发生率均无显著性差异（P〉0．05）。结论埃索美拉唑、丽珠维三联治疗HP感染根除率高，安全性较好。

Objective： ReseaRch esomepRazole, Livzon Weisanlian eRadication of HelicobacteR pyloRi infection the efficacy and safety.Mthods： GastRoscopy seen foR chronic gastRitis, C^14 bReath test-positive patients with 122 cases, weRe Randomly divided into tReatment gRoup 60 cases, given esomepRazole, Livzon Weisanlian. 62 cases of the contRol gRoup, to give esomepRazole, amoxicillin, metRonidazole theRapy, tReatment 1 week. Review 4 weeks afteR stopping GastRoscopy and CTM bReath test. Results： TReatment gRoup and contRol gRoup the eRadication Rate of HP weRe significantly diffeRent （P〈0.05） , symptom Remission Rate, incidence of adveRse Reactions weRe not significantly diffeRent （P〉0.05） .Conclusions： EsomepRazole, LivzonWeisanlian HP therapy clinical effects of infection, and eRadication Rates, betteR secuRity.